InflaRx Halts Phase 3 Trial for Vilobelimab Due to Futility
Ticker: IFRX · Form: 6-K · Filed: May 28, 2025 · CIK: 1708688
Sentiment: bearish
Topics: clinical-trial-halt, futility, drug-development, biotech
TL;DR
InflaRx trial stopped for futility, bad news for vilobelimab.
AI Summary
On May 28, 2025, InflaRx N.V. announced that the Independent Data Monitoring Committee recommended stopping their Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility. This decision was based on an interim analysis of the first 30 patients enrolled in the study.
Why It Matters
The discontinuation of this trial suggests a significant setback for InflaRx's development of vilobelimab for pyoderma gangrenosum, potentially impacting its future revenue streams and market position.
Risk Assessment
Risk Level: high — The trial being stopped for futility is a major negative development for the company's lead drug candidate.
Key Numbers
- 30 — patients (Number of patients analyzed in the interim futility analysis)
Key Players & Entities
- InflaRx N.V. (company) — Registrant
- vilobelimab (drug) — Investigational drug
- pyoderma gangrenosum (disease) — Indication for vilobelimab
- Independent Data Monitoring Committee (organization) — Oversight committee for the trial
- May 28, 2025 (date) — Date of announcement
FAQ
What was the specific reason for stopping the Phase 3 trial of vilobelimab?
The Independent Data Monitoring Committee recommended stopping the trial due to futility, based on data from the first 30 patients.
What is the indication for vilobelimab in this trial?
The trial was for vilobelimab in pyoderma gangrenosum.
When was this announcement made?
The announcement was made on May 28, 2025.
What is the name of the company filing this report?
The company filing this report is InflaRx N.V.
What type of report is this filing?
This filing is a Form 6-K, a Report of Foreign Private Issuer.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 28, 2025 regarding InflaRx N.V. (IFRX).